ARTICLE | Finance
Intranasal option
Why Canaan is backing Dauntless' intranasal somatostatin analog
February 25, 2017 1:01 AM UTC
Canaan Partners sees a clear market opportunity for a non-invasive somatostatin analog, prompting the VC to lead a $25 million series A extension for Dauntless Pharmaceuticals Inc.
The financing, announced Feb. 16, brings the round's final close to $32 million. Existing investor Sofinnova Ventures also participated. ...
BCIQ Company Profiles